Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Prostate Carcinoma: early-phase trial registry
14 of 38 indexed Metastatic Prostate Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #393 of 28,707 conditions by registered trial count.
38 US clinical trials · 14 currently recruiting · #393 of 28,707 conditions by registered trial count
Metastatic Prostate Carcinoma: 38 US clinical trials tracked, 14 recruiting.
Metastatic Prostate Carcinoma is the subject of 38 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 29 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition metastatic-prostate-carcinoma
OPEN 14 | RECR 37% | LATE 2 | EARLY 29 | RANK #393 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Alcohol Consumption (37% recruiting · 19 trials)
Metastatic Prostate Carcinoma lists 14 open slots (37% of 38 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Prostate Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Prostate Carcinoma is recruiting below its size-band peers.
14 of 38 indexed trials (36.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Prostate Carcinoma research.
M.D. Anderson Cancer Center accounts for 6 of 38 trials (15.8%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Prostate Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 38 trials that report a genuine target (sentinel values excluded). 27 of those (71.1%) plan for fewer than 100 participants.
-
Metastatic Prostate Carcinoma research is mostly interventional.
35 interventional and 3 observational studies make up this index (92.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
38 total, page 1 of 1
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group
NCT04423211
Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
NCT06422455
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
Mayo Clinic
NCT05045066
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
City of Hope Medical Center
NCT05869682
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
NCT06244004
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Thomas Jefferson University
NCT05487846
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Dana-Farber Cancer Institute
NCT06040125
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
NCT04489719
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
NCT04693377
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
NCT07073794
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
NCT05398302
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Thomas Jefferson University
NCT05627219
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
NCT05805371
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
NCT06305598
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT02703623
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT04592237
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
NCT03016741
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Mayo Clinic
NCT01953640
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
NCT02893917
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
Alliance for Clinical Trials in Oncology
NCT05241860
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
NCT03517969
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Northwestern University
NCT03012321
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT04388852
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT03821792
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
NCT02522715
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Mamta Parikh
NCT02807805
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Thomas Hope
NCT04716725
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT02881242
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
NCT03873805
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
NCT04267887
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04050215
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
NCT01881867
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
NCT01503229
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
NCT02458716
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Emory University
NCT03448458
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
NCT02598895
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Roswell Park Cancer Institute
NCT02159950
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 20 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Prostate Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Prostate Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Prostate Carcinoma page
38 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Metastatic Prostate Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Metastatic Prostate Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Prostate Carcinoma condition card totals 38 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.